Patents by Inventor Suryaprakash Sambhara
Suryaprakash Sambhara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250152696Abstract: An adenoviral vector with E1 and E3 regions removed and expressing the nucleoprotein or other immunogenic domain(s) of an influenza virus with or without the presence of the Autophagy-Inducing Peptide C5 (AIP-C5) from the CFP10 protein of Mycobacterium tuberculosis, compositions comprising same, and methods of use for general vaccination against heterosubtypic influenza viruses.Type: ApplicationFiled: August 13, 2022Publication date: May 15, 2025Inventors: Suresh MITTAL, Suryaprakash SAMBHARA, Ekramy SAYEDAHMED, Chinnaswamy JAGANNATH
-
Publication number: 20220062357Abstract: The present disclosure provides method and composition for protection, prevention, and/or treatment against viral infections via activation of ILCs induced by certain virus, including but not limited to, influenza and/or non-replicating adenoviruses. The present disclosure further provides that activation of ILCs is an intervention strategy against not only influenza viral infectious epidemic and/or pandemic before a strain-matched vaccine is available but also against other viruses for which prophylactic vaccines may not be available.Type: ApplicationFiled: August 24, 2021Publication date: March 3, 2022Applicants: Purdue Research Foundation, The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Mittal Suresh, Suryaprakash Sambhara, Weiping Cao, Wadzanai Mboko, Ekramy Sayedahmed
-
Patent number: 8163545Abstract: The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering such adenovirus vectors or recombinant adenovirus are also provided.Type: GrantFiled: December 23, 2009Date of Patent: April 24, 2012Assignees: United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Purdue Research FoundationInventors: Suryaprakash Sambhara, Jacqueline Katz, Mary Hoelscher, Suresh K. Mittal, Dinesh S. Bangari
-
Publication number: 20120009130Abstract: The present disclosure provides compositions and methods of enhancing resistance to viral infections through targeted delivery of 5?PPP negative stranded siRNA via nanoparticles, specifically gold nanorods. The 5?PPP activates type I interferon through the signaling cascade providing a novel therapeutic and prophylactic for seasonal and pandemic influenza. The technology described herein also extends the findings to the use of nanoparticles for delivery of genetic material including but not limited to siRNA and microRNA to accomplish targeted nanoparticle based gene therapy.Type: ApplicationFiled: May 6, 2011Publication date: January 12, 2012Applicant: NANOAXISInventors: Krishnan Chakravarthy, Suryaprakash Sambhara, Paul Knight
-
Publication number: 20100158939Abstract: The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering such adenovirus vectors or recombinant adenovirus are also provided.Type: ApplicationFiled: December 23, 2009Publication date: June 24, 2010Inventors: Suryaprakash Sambhara, Jacqueline Katz, Mary Hoelscher, Suresh K. Mittal, Dinesh S. Bangari
-
Publication number: 20100099745Abstract: The present disclosure provides compositions and methods for enhancing resistance to viral infections. The compositions include adenovirus vectors containing nucleic acid molecules encoding CARD domains from RIG-I and MDA5, recombinant adenoviruses and immunogenic compositions comprising such recombinant adenovirus vectors and adenoviruses. Methods for enhancing resistance to viral infections involving administering such adenovirus vectors or recombinant adenovirus are also provided.Type: ApplicationFiled: October 16, 2007Publication date: April 22, 2010Inventors: Suryaprakash Sambhara, Zha Guo
-
Publication number: 20080248057Abstract: Immunogenic compositions for administration to adults particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition when formulated as a vaccine for in vivo administration do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant.Type: ApplicationFiled: May 21, 2008Publication date: October 9, 2008Inventors: George A. Cates, Suryaprakash Sambhara, David Burt, Michel H. Klein
-
Publication number: 20080187557Abstract: The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering such adenovirus vectors or recombinant adenovirus are also provided.Type: ApplicationFiled: April 10, 2006Publication date: August 7, 2008Inventors: Suryaprakash Sambhara, Jacqueline Katz, Mary Hoelscher, Suresh K. Mittal, Dinesh S. Bangari
-
Patent number: 7169395Abstract: Immunogenic compositions for administration to adults, particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and by influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition, when formulated as a vaccine for in vivo administration, do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant.Type: GrantFiled: December 16, 1999Date of Patent: January 30, 2007Assignee: Sanofi Pasteur LimitedInventors: George A. Cates, Suryaprakash Sambhara, David Burt, Michel H. Klein
-
Publication number: 20060159700Abstract: Immunogenic compositions for administration to adults particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition when formulated as a vaccine for in vivo administration do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant.Type: ApplicationFiled: September 17, 2003Publication date: July 20, 2006Inventors: George Cates, Suryaprakash Sambhara, David Burt, Michel Klein
-
Patent number: 6677127Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: September 13, 1999Date of Patent: January 13, 2004Assignee: Aventis Pasteur LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6641816Abstract: The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus recombinant and a vaccinal antigen, which is not a poxvirus. The immunological material may be any biological material useful as a vaccine e.g., a polypeptide characteristic of a pathogenic microorganism or associated with a tumoral disorder, a DNA plasmid encoding a peptide or a polypeptide characteristic of a pathogenic microorganism or a tumor-associated antigen, or an hapten coupled to a carrier molecule. The poxvirus may be a live, attenuated or inactivated virus or a recombinant virus. Recombinant virus may encode a heterologous polypeptide such as chemokines, cytokines or co-immunostimulatory molecules or an homologous polypeptide, which is immunologically cross reactive with the immunogenic polypeptide or peptide.Type: GrantFiled: March 9, 2001Date of Patent: November 4, 2003Assignee: Aventis Pasteur S.A.Inventors: Michel Chevalier, Bernard Meignier, Catherine Moste, Suryaprakash Sambhara
-
Patent number: 6486135Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: May 12, 2000Date of Patent: November 26, 2002Assignee: Aventis Pasteur LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6083925Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: March 5, 1999Date of Patent: July 4, 2000Assignee: Connaught Laboratories LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6022864Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein enclosing sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: March 27, 1998Date of Patent: February 8, 2000Assignee: Connaught Laboratories LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6017897Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: July 18, 1997Date of Patent: January 25, 2000Assignee: Pasteur Merieux Connaught CanadaInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 5843913Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: June 7, 1996Date of Patent: December 1, 1998Assignee: Connaught Laboratories LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein